Efficacy and safety of iguratimod on patients with relapsed or refractory IgG4-related disease.
Yanying LiuYuxin ZhangWenjie BianJiangnan FuXing SunDa ChenJiali ChenXiaozhen ZhaoYingni LiWen ZhangZhanguo LiPublished in: Clinical rheumatology (2019)
Iguratimod can be a therapeutic strategy to achieve remission in relapsed or refractory IgG4-RD patients inadequately responding to corticosteroid treatment with or without other immunosuppressant treatment. Key messages • Iguratimod was effective for relapsed or refractory IgG4-RD patients. • Iguratimod can improve the clinical symptoms of patients, reduce the serum IgG and IgG4 levels, and can also reduce the volume of involved glands.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- acute lymphoblastic leukemia
- acute myeloid leukemia
- peritoneal dialysis
- diffuse large b cell lymphoma
- rheumatoid arthritis
- physical activity
- systemic lupus erythematosus
- patient reported outcomes
- hodgkin lymphoma
- depressive symptoms
- combination therapy